Europe Viscosupplementation Market, By Source (Non-Animal Origin and Animal Origin), Molecular Weight (Intermediate Molecular Weight, Low Molecular Weight, and High Molecular Weight), Injection (Single Injection, Three Injection, and Five Injection), Age Group (Geriatric and Adult), End User (Hospitals, Orthopaedic Clinics, Ambulatory Care Center, and Others), Distribution Channel (Direct Tender and Retail Sales) - Industry Trends and Forecast to 2030.
Europe Viscosupplementation Market Analysis and Insights
Viscosupplements available in the market have shown clinical efficacy and are proven to be the most effective treatment for knee osteoarthritis. Osteoarthritis is a chronic painful degenerative joint disease and is the leading cause of chronic disability. The onset of the condition is mostly after 30 years of age, which may progress to develop into a disability after ten years of diagnosis.
Furthermore, the increasing demand for non-surgical treatments for osteoarthritis, the prevalence of lifestyle-induced disorders, and advancements in the development of hyaluronic acid-based therapies are some of the factors that are expected to drive the market.
The increase in the target population and a growing preference for alternative treatment options for corticosteroids for joint pain management are expected to significantly propel the product demand during the forecast period.
However, the high cost associated with the drug and side effects such as temporary injection-site pain, swelling, heat or redness, rash or itching, bruising around the joint, and fluid accumulation in the injected knee may restrain the market's growth.
Data Bridge Market Research analyzes that the Europe viscosupplementation market is expected to reach the value of USD 821.05 million by 2030, at a CAGR of 8.0% during the forecast period. This market report also covers pricing analysis, patent analysis, and technological advancements in depth.
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customisable 2015-2020) |
|
Quantitative Units |
Revenue in Million, Volumes in Units, and Pricing in USD |
|
Segments Covered |
Source (Non-Animal Origin and Animal Origin), Molecular Weight (Intermediate Molecular Weight, Low Molecular Weight, and High Molecular Weight), Injection (Single Injection, Three Injection, and Five Injection), Age Group (Geriatric and Adult), End User (Hospitals, Orthopedic Clinics, Ambulatory Care Center, and Others), Distribution Channel (Direct Tender and Retail Sales) |
|
Countries Covered |
Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Poland, Austria, Hungary, Norway, Ireland, Portugal, and Rest of Europe |
|
Market Players Covered |
Anika Therapeutics, Inc., SEIKAGAKU CORPORATION, Bioventus, Fidia Farmaceutici S.p.A, Ferring B.V, sanofi-aventis U.S. LLC, Zimmer Biomet, APTISSEN, Johnson & Johnson Services, Inc., LG Chem., Viatris Inc., IBSA Institut Biochimique SA, TRB CHEMEDICA SA, and Teva Pharmaceutical Industries Ltd. among others |
Europe Viscosupplementation Market Definition
Viscosupplementation is a therapeutic process in which the pathological synovial fluid or effusion is removed from the joint by arthrocentesis and is replaced with a highly purified hyaluronan solution which has a 16- to 30-times greater concentration than the pathological joint fluid, and a 2- to 5-times than that of the hyaluronan in the healthy synovial fluid. In some preparations of hyaluronan for therapeutic purposes, the rheological properties (viscosity and elasticity) are low, and therefore the elastoviscosity of the fluid is similar to that of fluid removed from an arthritic joint. Another preparation available to patients worldwide is composed of hyaluronan derivatives (hylans) with substantially greater elastoviscosity than hyaluronan solutions and has comparable rheological properties to those of the fluid found in young, healthy individuals.
Europe Viscosupplementation Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Rising Geriatric Population
With this increasing age comes a reciprocal increase in the number of elderly patients admitted to hospitals due to fatal traumatic injuries. Along with that, the rising prevalence of knee osteoarthritis diseases leads to increasing demand for diagnosis and treatment. The increasing need for proper treatment proportionally surges the demand for care, services, and technologies for the prevention and treatment of knee osteoarthritis conditions such as osteoporosis, osteopenia, and other complications. The elderly population is more prone to these conditions leading to fragile bones and joints. Viscosupplementation is used in the procedure to provide such patients with immediate and efficient benefits associated with their bodies.
- Increasing Risk of Osteoporosis and Osteoarthritis
Osteoporosis is a disease of bone that progresses due to less bone mineral density and bone mass or due to some variation in the quality or structure of bone. Osteoporosis could increase the risk of fractures leading to broken bones due to decreased bone strength. It is more observed in women as compared to men. The post-menstrual women often get bone fractures due to osteoporosis as the disease shows no symptoms. Most elderly people are more prone to osteoporosis. Osteoarthritis is a joint disease or an inflammation of the joints and surrounding tissues. The mobility of a person is affected when such conditions occur.
Silent diseases such as osteoporosis and osteoarthritis show no symptoms and weaken the person's bone, leading to major fatalities such as spine malformation, fracture, sudden fall, or breakage of bone among others. Thus, the increased risks of these conditions directly enhance the demand for viscosupplementation required to treat the malformations that happened due to such conditions. Therefore, the increasing risk of osteoporosis and osteoarthritis is anticipated to drive the growth of the Europe viscosupplementation market.
Opportunity
- Safety and Effectiveness of Intra-Articular Hyaluronic Acid (IAHA)
There are several types of hyaluronic acid injections, also called viscosupplementation, that are used for knee osteoarthritis. They are made from either rooster or chicken combs or are derived from bacteria and are injected directly into the joint. Intra-articular hyaluronic acid is a U.S. Food and Drug Administration-approved treatment for knee osteoarthritis (OA). Intra-articular hyaluronic acid (IAHA) injection presents an alternative local treatment option providing symptomatic benefit without the systemic AEs associated with IA corticosteroids. Numerous RCTs and meta-analyses have sought to assess the efficacy and safety of IAHA, with mixed results and conclusions. IAHA is demonstrated to have a positive effect on pain and joint function. There is also mounting data showing that multiple courses of IAHA can impact long-term outcomes, including a reduction in concomitant analgesia use and a delay in the need for total knee replacement surgery.
Restraints/ Challenges
- Side-Effects of Viscosupplementation
The wide ranges of viscosupplementation are used by professionals for performing osteoarthritis procedures on various patients of different age groups. The products are used for joint replacement, hip arthroscopy, and shoulder arthroscopy, among more. As viscosupplementation benefits the patients by maintaining their range of motion, flexibility, and movement, there are various health complications associated with it. Thus, side effects and complications associated with the use of viscosupplementation are hampering the demand for viscosupplementation in the market.
- Lack of Technical Expertise
Finding, attracting, and hiring talent is also the first step in building a professional bench of engineers and technicians. Even in the best of circumstances, this procedure can be challenging. Manufacturing existing workforce is rapidly aging and retiring. In the medical industry, there is a scarcity of STEM (science, technology, engineering, and mathematics) skills. Although demand for skilled tradespeople (technicians) and undergraduate/post-graduate skills (engineers) remains strong in manufacturing, the number of people with the necessary skills is approaching a trickle. Only trained professionals should perform viscosupplementation, but across the globe, this number is much less as these procedures are complex.
However, putting together a good additive manufacturing (AM) workforce entails more than just finding and recruiting qualified candidates. Employees must be qualified to remain current and maintain the required skills as technology shift and grow. Even with their STEM-focused education, newly minted engineers would certainly need on-the-job training in AM techniques, which is one of the major challenges of recruiting and hiring them. Indeed, many undergraduate engineering programs provide little in the way of AM-specific education, and as a result, many graduates can lack the AM skills that employers seek.
Recent Developments
- In May 2022, Fidia Farmaceutici S.p.A. harnessed the regenerative power of hyaluronic acid with its innovative portfolio launched in Spain. Fidia Farmaceutici S.p.A. presented its Aesthetic Care portfolio with a scientific symposium on its innovative ACP (Auto-Crosslinked Polymer) technology at the 20th Aesthetic & Anti-aging Medicine World Congress 2022 (AMWC) in Monte Carlo. The company launched its complete Hyal System and Hy-Tissue portfolio in Spain. This helped the company to showcase its research for hyaluronic acid.
- In August 2021, SEIKAGAKU CORPORATION (announced the launch of HyLink, an intra-articular single-injection viscosupplement for the treatment of knee osteoarthritis in Taiwan, through TCM Biotech International Corp. HyLink is an intra-articular single-injection viscosupplement for the treatment of knee osteoarthritis whose main ingredient is a cross-linked hyaluronate hydrogel made using Seikagaku's unique cross-linking technology. This helped the company to expand its product portfolio.
Europe Viscosupplementation Market Scope
Europe viscosupplementation market is segmented into source, age group, molecular weight, injection, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Source
- Animal Origin
- Non-Animal Origin
On the basis of source, the Europe viscosupplementation market is segmented into animal origin and non-animal origin.
Molecular Weight
- High Molecular Weight
- Low Molecular Weight
- Intermediate Molecular Weight
On the basis of molecular weight, the Europe viscosupplementation market is segmented into intermediate molecular weight, low molecular weight, and high molecular weight.
Injection
- Single Injection
- Three Injection
- Five Injection
On the basis of injection, the Europe viscosupplementation market is segmented into single injection, three injection, and five injection.
Age Group
- Adult
- Geriatric
On the basis of age group, the Europe viscosupplementation market is segmented into geriatric and adult.
End User
- Hospitals
- Orthopedic Clinics
- Ambulatory Care Center
- Others
On the basis of end user, the Europe viscosupplementation market is segmented into hospitals, orthopedic clinics, ambulatory care center, and others.
Distribution Channel
- Direct Tender
- Retail Sales
On the basis of distribution channel, the Europe viscosupplementation market is segmented into direct tender and retail sales.
Europe Viscosupplementation Market Regional Analysis/Insights
The Europe viscosupplementation market is analyzed and market size information is provided by source, age group, molecular weight, injection, end user, and distribution channel.
The countries covered in this market report Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Poland, Austria, Hungary, Norway, Ireland, Portugal, and the rest of Europe.
Germany is expected to dominate the Europe region due to a growing preference for short treatment regimens, even though high prices, and growing prevalence of target diseases, such as osteoarthritis, and an increasing number of government approvals for three-injection viscosupplements are expected to positively impact the segment growth.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Europe Viscosupplementation Market Share Analysis
Europe viscosupplementation market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus on the market.
Some of the major players operating in the Europe viscosupplementation market are Anika Therapeutics, Inc., SEIKAGAKU CORPORATION, Bioventus, Fidia Farmaceutici S.p.A, and Ferring B.V, sanofi-aventis U.S. LLC, Zimmer Biomet, APTISSEN, Johnson & Johnson Services, Inc., LG Chem., Viatris Inc., IBSA Institut Biochimique SA, TRB CHEMEDICA SA, and Teva Pharmaceutical Industries Ltd. among others.
SKU-
